Chengda Biology: Core product freeze-dried human rabies vaccine increases approved simple 4-dose immunization program.

The announcement of Chengda Bio stated that the company's core product, the freeze-dried human rabies vaccine, has been approved by the National Medical Products Administration to add a simple 4-dose immunization program on top of the existing immunization program, and revise the instructions and label content. This vaccine is the first domestically marketed Vero cell human rabies vaccine, with the original Zagreb 2-1-1 and Essen 5-dose programs, and the addition of the simple 4-dose program will form three different immunization program layouts. The recommended procedure for the simple 4-dose program is for general bite victims to inject 1 dose on any of the days 0, 3, 7, and 14-28, a total of 4 doses, with a concise and flexible vaccination process that can enhance vaccination convenience and completion rates, catering to different populations and exposure scenarios.